Edgewise Therapeutics Stock Today

EWTX Stock  USD 22.42  0.09  0.40%   

Performance

11 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Less than 44

 
High
 
Low
Below Average
Edgewise Therapeutics is trading at 22.42 as of the 13th of July 2024; that is 0.40 percent increase since the beginning of the trading day. The stock's open price was 22.33. Edgewise Therapeutics has about a 44 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Edgewise Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of June 2024 and ending today, the 13th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
26th of March 2021
Category
Healthcare
Classification
Health Care
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. Edgewise Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 93.41 M outstanding shares of which 8.48 M shares are currently shorted by private and institutional investors with about 13.88 trading days to cover. More on Edgewise Therapeutics

Moving against Edgewise Stock

  0.58IKT Inhibikase TherapeuticsPairCorr
  0.35FLGC Flora Growth CorpPairCorr
  0.34VALN Valneva SE ADRPairCorr
  0.33FENC Fennec PharmaceuticalsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Edgewise Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentKevin Koch
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities10.9 M16.8 M
Way Down
Slightly volatile
Non Current Liabilities Total4.2 M4.4 M
Notably Down
Pretty Stable
Total Assets252.6 M340 M
Way Down
Slightly volatile
Total Current Assets245 M327 M
Way Down
Slightly volatile
Debt Levels
Edgewise Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Edgewise Therapeutics' financial leverage. It provides some insight into what part of Edgewise Therapeutics' total assets is financed by creditors.
Liquidity
Edgewise Therapeutics currently holds 5.41 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Edgewise Therapeutics has a current ratio of 26.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Edgewise Therapeutics' use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

6.03 Million
Edgewise Therapeutics (EWTX) is traded on NASDAQ Exchange in USA. It is located in 1715 38th Street, Boulder, CO, United States, 80301 and employs 92 people. Edgewise Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.09 B. Edgewise Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 93.41 M outstanding shares of which 8.48 M shares are currently shorted by private and institutional investors with about 13.88 trading days to cover. Edgewise Therapeutics currently holds about 248.4 M in cash with (91.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99.
Check Edgewise Therapeutics Probability Of Bankruptcy
Ownership Allocation
The majority of Edgewise Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Edgewise Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Edgewise Therapeutics. Please pay attention to any change in the institutional holdings of Edgewise Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Edgewise Ownership Details

Edgewise Stock Institutional Holders

InstituionRecorded OnShares
Tcg Crossover Management, Llc2024-03-31
2.3 M
Vr Adviser, Llc2024-03-31
1.8 M
Hhg Plc2024-03-31
1.8 M
Goldman Sachs Group Inc2024-03-31
1.7 M
New Leaf Venture Partners, L.l.c.2024-03-31
1.6 M
Geode Capital Management, Llc2024-03-31
1.4 M
Driehaus Capital Management Llc2024-03-31
1.3 M
Ecor1 Capital, Llc2024-03-31
1.3 M
State Street Corporation2024-03-31
1.2 M
Orbimed Advisors, Llc2024-03-31
15 M
Ra Capital Management, Llc2024-03-31
8.9 M
View Edgewise Therapeutics Diagnostics

Edgewise Therapeutics Historical Income Statement

At this time, Edgewise Therapeutics' Total Other Income Expense Net is fairly stable compared to the past year. View More Fundamentals

Edgewise Stock Against Markets

Edgewise Therapeutics Corporate Management

Badreddin EdrisCoFounder DirectorProfile
John MooreGeneral CounselProfile
Behrad DerakhshanChief OfficerProfile
Marc MDChief OfficerProfile
Alan RussellChief CoFounderProfile

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.